Oxford Epilepsy Research Group
- 01865 231891
Founded in 2012 by Arjune Sen, Masud Husain, Karri Lämsä and Angela Vincent
Galvanises research into epilepsy across OUH NHS Trust, Oxford Health and University of Oxford
Extensive national and international collaborations
We are a forward-looking dynamic group interested in all aspects of clinical and experimental epileptology with an emphasis on clinically relevant research. The Group draws together all relevant disciplines across Oxford University Hospitals and the University of Oxford.
What is epilepsy?
The word epilepsy derives from the Greek word epilambanein, meaning ‘to seize’. One in 20 people will have a seizure at some point in their life, and around one in 130 people will develop epilepsy. It is one the most common serious neurological conditions, affecting 600,000 patients in the UK and 50 million people worldwide. As epilepsy often affects people across their lifetime, its socioeconomic impact is substantial.
Epilepsy represents far more than seizures alone; it commonly associates with cognitive, psychological and psychosocial difficulties. To advance care for people with epilepsy, each person must be viewed as an individual and holistically. We are developing research and clinical pathways to address co-morbidities associated with epilepsy, as well as aiming to improve our understanding of why seizures occur. Our role is to always try and enable people with epilepsy to achieve their full potential. By increasing our understanding of the processes that underlie a patient’s symptoms we will be able to better deliver on that ambition.
The Oxford Epilepsy Research Group capitalises on the clinical expertise available at the John Radcliffe Hospital and the wider basic scientific research performed within University of Oxford. We believe in an open, transparent and collaborative approach and all our research is pursued with the aim of delivering better patient care
There are particular strengths in antibody-mediated epilepsy and novel/ ultra-high-field imaging in epilepsy. We have strong links with genomic research into epilepsy and are developing many research projects to better evaluate co-morbidity in epilepsy, an area of epileptology that is often rather overlooked.
We believe that all patients should be given every opportunity to fulfil their potential. To better achieve this, we have established and are developing the Oxford Super-Specialist Epilepsy MDT Clinics. Consultants refer patients to these clinics.
a) On the third Friday of each month – Cognitive Disorders and Epilepsy (Arjune Sen, Chris Butler, Ian Brown, Maggie Tristram). This unique clinic is for patients with epilepsy of working age who have significant cognitive or employment related issues. Patients are evaluated holistically by the team members who then issue a joint letter outlining possible approaches and solutions
b) On the fourth Friday of alternate months – Learning Difficulties and Epilepsy (Arjune Sen, Tim Andrews, Maggie Tristram, Jackie Roberts). Patients with learning difficulties and epilepsy, conditions that commonly exist together, are seen with their Family and carers by Consultants and Specialist Nurses with expertise in epilepsy and Learning difficulty to try and disentangle seizure related issues from other aspects of care and offer clear pathways to try and improve care
c) On the first Friday of alternate months – Neuropsychiatry and Epilepsy, currently being developed
- Arjune Sen (Nuffield Department of Clinical Neurosciences)
- Masud Husain (Nuffield Department of Clinical Neurosciences)
- Karri Lämsä (Department of Pharmacology)
- Angela Vincent (Nuffield Department of Clinical Neurosciences)
- Maria Emilia Andraus
- Christian Bien, Head of Epilepsy at Krankenhaus Mara, Bethel, Germany
- Rüdiger Köhling, Director of the Oscar Langendorff Institute, Rostock, Germany
- Mark Richardson, Chair of Epileptology, Kings College London
- Ernest Somerville, Head of Comprehensive Epilepsy Centre, Prince of Wales Hospital, Sydney
- Matthew Walker, Head of Department of Clinical and Experimental Epilepsy, University College London
- Olaf Ansorge (Nuffield Department of Clinical Neurosciences)
- Christopher Butler (Nuffield Department of Clinical Neurosciences)
- Zam Cader (Nuffield Department of Clinical Neurosciences)
- Marco Capogna (Anatomical Neuropharmacology Unit)
- Alex Green (Nuffield Department of Surgery)
- Sarosh Irani (Nuffield Department of Clinical Neurosciences)
- S. John Jacob (Nuffield Department of Clinical Neurosciences)
- John Jefferys (Department of Pharmacology)
- Usha Kini (Wellcome Trust Centre for Human Genetics)
- Bethan Lang (Nuffield Department of Clinical Neurosciences)
- Michael Sharpe (Department of Psychiatry)
- Peter Somogyi (Anatomical Neuropharmacology Unit)
- Mark Stokes (Oxford Centre for Human Brain Activity)
- Jenny Taylor (Wellcome Trust Centre for Human Genetics)
- Natalie Voets (Nuffield Department of Clinical Neurosciences)